Literature DB >> 24736382

Altered interactions between cardiac myosin binding protein-C and α-cardiac actin variants associated with cardiomyopathies.

Melissa L Chow1, Justin F Shaffer2, Samantha P Harris3, John F Dawson4.   

Abstract

The two genes most commonly associated with mutations linked to hypertrophic or dilated cardiomyopathies are β-myosin and cardiac myosin binding protein-C (cMyBP-C). Both of these proteins interact with cardiac actin (ACTC). Currently there are 16 ACTC variants that have been found in patients with HCM or DCM. While some of these ACTC variants exhibit protein instability or polymerization-deficiencies that might contribute to the development of disease, other changes could cause changes in protein-protein interactions between sarcomere proteins and ACTC. To test the hypothesis that changes in ACTC disrupt interactions with cMyBP-C, we examined the interactions between seven ACTC variants and the N-terminal C0C2 fragment of cMyBP-C. We found there was a significant decrease in binding affinity (increase in Kd values) for the A331P and Y166C variants of ACTC. These results suggest that a change in the ability of cMyBP-C to bind actin filaments containing these ACTC protein variants might contribute to the development of disease. These results also provide clues regarding the binding site of the C0C2 fragment of cMyBP-C on F-actin.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiac actin; Cardiomyopathy; Heart disease; Myosin binding protein-C

Mesh:

Substances:

Year:  2014        PMID: 24736382      PMCID: PMC4306385          DOI: 10.1016/j.abb.2014.04.003

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  31 in total

1.  Clinical and genetic characteristics of alpha cardiac actin gene mutations in hypertrophic cardiomyopathy.

Authors:  J Mogensen; A Perrot; P S Andersen; O Havndrup; I C Klausen; M Christiansen; P Bross; H Egeblad; H Bundgaard; K J Osterziel; G Haltern; H Lapp; P Reinecke; N Gregersen; A D Børglum
Journal:  J Med Genet       Date:  2004-01       Impact factor: 6.318

2.  Functional consequences of a mutation in an expressed human alpha-cardiac actin at a site implicated in familial hypertrophic cardiomyopathy.

Authors:  Carol S Bookwalter; Kathleen M Trybus
Journal:  J Biol Chem       Date:  2006-04-12       Impact factor: 5.157

3.  Actin mutations in dilated cardiomyopathy, a heritable form of heart failure.

Authors:  T M Olson; V V Michels; S N Thibodeau; Y S Tai; M T Keating
Journal:  Science       Date:  1998-05-01       Impact factor: 47.728

4.  A periodic pattern of evolutionarily conserved basic and acidic residues constitutes the binding interface of actin-tropomyosin.

Authors:  Bipasha Barua; Patricia M Fagnant; Donald A Winkelmann; Kathleen M Trybus; Sarah E Hitchcock-DeGregori
Journal:  J Biol Chem       Date:  2013-02-18       Impact factor: 5.157

Review 5.  Earning stripes: myosin binding protein-C interactions with actin.

Authors:  Sabine J van Dijk; Kristina L Bezold; Samantha P Harris
Journal:  Pflugers Arch       Date:  2014-01-19       Impact factor: 3.657

6.  Factors affecting polyacrylamide gel electrophoresis and electroblotting of high-molecular-weight myofibrillar proteins.

Authors:  J D Fritz; D R Swartz; M L Greaser
Journal:  Anal Biochem       Date:  1989-08-01       Impact factor: 3.365

7.  Alpha-cardiac actin is a novel disease gene in familial hypertrophic cardiomyopathy.

Authors:  J Mogensen; I C Klausen; A K Pedersen; H Egeblad; P Bross; T A Kruse; N Gregersen; P S Hansen; U Baandrup; A D Borglum
Journal:  J Clin Invest       Date:  1999-05-15       Impact factor: 14.808

8.  Expression of actin mutants to study their roles in cardiomyopathy.

Authors:  Lori A Rutkevich; David J Teal; John F Dawson
Journal:  Can J Physiol Pharmacol       Date:  2006-01       Impact factor: 2.273

9.  Functional studies of yeast actin mutants corresponding to human cardiomyopathy mutations.

Authors:  W W Wong; T C Doyle; P Cheung; T M Olson; E Reisler
Journal:  J Muscle Res Cell Motil       Date:  2001       Impact factor: 2.698

10.  Prevalence and spectrum of thin filament mutations in an outpatient referral population with hypertrophic cardiomyopathy.

Authors:  Sara L Van Driest; Erik G Ellsworth; Steve R Ommen; A Jamil Tajik; Bernard J Gersh; Michael J Ackerman
Journal:  Circulation       Date:  2003-07-14       Impact factor: 29.690

View more
  6 in total

1.  The myosin mesa and a possible unifying hypothesis for the molecular basis of human hypertrophic cardiomyopathy.

Authors:  James A Spudich
Journal:  Biochem Soc Trans       Date:  2015-02       Impact factor: 5.407

2.  Functional Characterization of Cardiac Actin Mutants Causing Hypertrophic (p.A295S) and Dilated Cardiomyopathy (p.R312H and p.E361G).

Authors:  Roua Hassoun; Constanze Erdmann; Sebastian Schmitt; Setsuko Fujita-Becker; Andreas Mügge; Rasmus R Schröder; Matthias Geyer; Mina Borbor; Kornelia Jaquet; Nazha Hamdani; Hans Georg Mannherz
Journal:  Int J Mol Sci       Date:  2022-04-18       Impact factor: 6.208

Review 3.  Three perspectives on the molecular basis of hypercontractility caused by hypertrophic cardiomyopathy mutations.

Authors:  James A Spudich
Journal:  Pflugers Arch       Date:  2019-02-15       Impact factor: 3.657

4.  Assessment of the Contribution of a Thermodynamic and Mechanical Destabilization of Myosin-Binding Protein C Domain C2 to the Pathomechanism of Hypertrophic Cardiomyopathy-Causing Double Mutation MYBPC3Δ25bp/D389V.

Authors:  Frederic V Schwäbe; Emanuel K Peter; Manuel H Taft; Dietmar J Manstein
Journal:  Int J Mol Sci       Date:  2021-11-04       Impact factor: 5.923

Review 5.  Classifying Cardiac Actin Mutations Associated With Hypertrophic Cardiomyopathy.

Authors:  Evan A Despond; John F Dawson
Journal:  Front Physiol       Date:  2018-04-17       Impact factor: 4.566

Review 6.  Actin Mutations and Their Role in Disease.

Authors:  Francine Parker; Thomas G Baboolal; Michelle Peckham
Journal:  Int J Mol Sci       Date:  2020-05-10       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.